In 2023, Juan P Frias and colleagues, in The Lancet, published the first phase two clinical trial of orforglipron, which investigated the use of a small-molecule oral GLP-1R agonist called orforglipron in type 2 diabetes, which can be taken at any time of the day without restrictions on food and water intake (Frias et al., 2023)
*Only available by prescription from provider after virtual consultation
However, even diabetes-related semaglutide coverage sometimes excludes dosing higher than 1 mg weekly, the standard diabetes maintenance dose, while Wegovy therapy typically requires 2.4 mg weekly for maximal weight loss benefit
While the 2025 Kuceki study showed stronger results with clinical tattooing (26.5% area regrowth), this trial proves that a simple spray still produces statistically significant improvement
K.KassG
Reconstitution is the technical term for the process of adding a liquidusually bacteriostatic waterto a dry powder to turn it back into a liquid solution that can be injected